Not a Member? Register Now
Email this page
Send the page "" to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
FDA Date: 06/27/2017
Revlimid (lenalidomide) REMS
Goals of the Revlimid (lenalidomide) REMS Program
The goals of the REVLIMID risk evaluation and mitigation strategy are as follows:1. To prevent the risk of embryo-fetal exposure to REVLIMID.2. To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for REVLIMID.
• Elements to Assure Safe Use• Implementation System